Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems

Definitions

• the invention relates to compounds which are to be used in the pharmaceutical industry as active ingredients for the production of medicaments.
• European patent application 150 586 discloses 2- (pyridylmethylthio- or -sulfinyl) benzimidazoles, which can be substituted in the pyridine part of the molecule in the 4-position, inter alia, by alkylthio or arylthio radicals. A long-lasting gastric acid secretion inhibition is given for the compounds described. - In international patent application W089 / 03830 it is described that the same, as well as other structure-like compounds, are said to be suitable for the treatment of osteoporosis.
• the invention relates to compounds of the formula I (see attached
• X represents CH or N
• Y is S, SO, SO-, 0, NH or N-1-4C-alkyl
• Rl is hydrogen, 1-4C-alkyl, 1-4C-alkoxy or halogen
• R2 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy, halogen, trifluoroethyl, completely or predominantly substituted by fluorine-1-4C-alkoxy, chlorodifluoromethoxy, 2-chloro-l, 1,2-trifluoroethoxy or together with R3, if desired, denotes completely or partially fluorine-substituted 1-2C-alkylene-dioxy or chlorotrifluoroethylene-dioxy,
• R3 is hydrogen, completely or predominantly substituted by fluorine-l4C-alkoxy, chlorodifluoromethoxy, 2-chloro-l, l, 2-trifluoroethoxy or together with R2, if desired, completely or partly substituted by fluorine-substituted l-2C-alkylenedioxy or chlorotrifluoroethylene dioxy means
• R4 is hydrogen, 1-4C-alkyl, 1-4C-alkyl substituted by R14, 1-4C-alkylcarbonyl, 2-4C-alkenyl carbonyl, halo-1-4C-alkylcarbonyl, N (R15) R16 -l-4C-alkyl carbonyl, Di-1-4C-alkyl carbamoyl or 1-4C-alkyl - sul fonyl,
• R5 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy
• R6 is a mono- or di-1-4C-alkylcarbamoyl or -thiocarbamoyl radical, an NI-4C-alkyl-N'-cyano-amidino radical, an INI-4C-alkylamino-2-nitroethylene radical, an N-2-propinyl -N'-cyano-amidino radical, an aminosulfonyl-a idino radical, or a cycle or bicyclic radical substituted by R8 and R9, which is selected from the group consisting of benzene, furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, Thiazoline, isothiazole, imidazole, imidazoline, pyrazole, triazole, tetrazole, thiadiazole, thiadiazole-1-oxide, oxadiazole, pyridine, pyridine-N-oxide, pyridine, triazine,
• R7 denotes hydrogen, 1-4C-alkyl or 1-4C-alkoxy
• R8 is hydrogen, 1-4C-alkyl, hydroxy, 1-4C-alkoxy, halogen, nitro, guanidino, carboxy, 1-4C-alkoxycarbonyl, 1-4C-A1-yl ' or -N (R11) R12 substituted by RIO means
• R9 denotes hydrogen, 1-4C-alkyl, hydroxy, 1-4C-alkoxy, fluorine or trifluoromethyl
• RIO is hydroxy, 1-4C-alkoxy, carboxy, 1-4C-alkoxycarbonyl or -N (R11) R12, where
• Rll hydrogen, 1-4C-alkyl or -C0-R13 and
• R12 is hydrogen or 1-4C-A1kyl, or wherein
• R11 and R12 together and including the nitrogen atom to which both are attached represent a piperidino or morpholino radical
• R13 denotes hydrogen, 1-4C-alkyl or 1-4C-alkoxy
• R14 is hydroxy, 1-4C-alkoxy, carboxy, 1-4C-alkoxycarbonyl or -N (R15) R16, where R15 is 1-4C-alkyl and R16 is 1-4C-alkyl, or wherein R15 and R16 together and including the nitrogen atom to which both are bonded represent a piperidino or morpholino radical, is a number from 2 to 7, n is the number 0 or 1, p is 0 or 1, q is 0, 1 or 2, r denotes a number from 2 to 7, t denotes the number 0 or 1 and u denotes a number from 0 to 7 and their salts, excluding those compounds of the formula I in which Y is S or SO and at the same time X is CH, t the number 0 means u the number 0, R4 is hydrogen or 1-4C-alkyl and R6 is a cycle or bicyclus which is substituted by R8 and R9 and is selected from the group consisting of benzene,
• 1-4C-A1kyl stands for straight-chain or branched alkyl radicals with 1 to 4 carbon atoms. Examples include the butyl, iso-butyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radicals.
• 1-4C-Alkoxy represents a radical which, in addition to the oxygen atom, contains one of the 1-4C-alkyl radicals mentioned above.
• the methoxy and ethoxy radicals may be mentioned, for example.
• Halogen in the sense of the present invention is bromine, chlorine and fluorine.
• 1,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, perfluoroethoxy and in particular 1,1,2 may be used as wholly or predominantly fluorine-substituted 1-4C-alkoxy , 2-tetrafluoroethoxy, the trifluoro ethoxy, the 2,2,2-trifluoroethoxy and the difluoro ethoxy.
• fluorine-substituted 1-2C-alkylenedioxy include, for example, methylenedioxy- (-0-CH -.- 0-), ethylenedioxy- (-0-CH 2 -CH - 0-), 1,1-difluoroethylene dioxy- (-0-CF 2 -CH 2 -0-), 1,1,2,2-tetrafluoroethylene dioxy- (-0-CF 2 -CF 2 -0-) and especially the difluoromethylene dioxy- ( -0-CF 2 -0-) and the 1,1,2-trifluoroethylene dioxy radical (-0-CF 2 -CHF-0-).
• R2 and R3 together mean all or part of fluorine-substituted 1-2C-alkylenedioxy or chlorotrifluoroethylenedioxy, the substituents R2 and R3 in adjacent positions - preferably at positions 5 and 6 - are bonded to the benzene part of the benzidazole ring.
• Exemplary 1-4C-alkyl radicals substituted by R14 are 2-methoxycarbonylethyl, 2-ethoxycarbonylethyl, methoxycarbonylethyl, carboxymethyl, 2-hydroxyethyl, methoxyethyl and 2-methoxyethyl , the Di ethylaminomethyl- and the 2-Dimethylaminoethylrest called.
• 1-4C-Alkylcarbonyl stands for a radical which, in addition to the carbonyl group, contains one of the 1-4C-alkyl radicals mentioned above.
• the acetyl radical may be mentioned.
• 2-4C-alkenylcarbonyl stands for a radical which, in addition to the carbonyl group, contains a 2-4C-alkenyl radical, for example a propenyl radical or a butenyl radical.
• a 2-4C-alkenyl radical for example a propenyl radical or a butenyl radical.
• the acryloyl radical may be mentioned.
• Halogen-1-4C-alkylcarbonyl stands for a radical which, in addition to the carbonyl group, contains a halogen-substituted 1-4C-alkyl radical.
• the ⁇ -chlorobutyryl radical may be mentioned.
• N (R15) R16-1-4C-alkylcarbonyl stands for a radical which, in addition to the carbonyl group, contains a 1-4C-alkyl radical which is substituted by -N (R15) R16.
• the 3-dimethylamino-propionyl radical may be mentioned.
• Di-1-4C-alkylcarbamoyl stands for a radical which, in addition to the carbonyl group, contains a di-1-4C-alkylamino radical.
• the di-1-4C-alkylamino radical is an amino radical which is substituted by two identical or different of the above-mentioned 1-4C-alkyl radicals. Examples include the dimethylamino, diethylamino and di-isopropylamino residues.
• the dimethylcarbamoyl and diethylcarbamoyl radicals may be mentioned as di-1-4C-alkylcarbamoyl radicals.
• 1-4C-Alkylsulfonyl stands for a radical which, in addition to the sulfonyl group (-SO «-), contains one of the 1-4C-alkyl radicals mentioned above.
• the methylsulfonyl radical may be mentioned as an example.
• Mono- or di-1-4C-alkylcarbamoyl radicals are carbamoyl radicals (-C0-NH-) which are substituted by one or two identical or different of the above-mentioned 1-4C-alkyl radicals. Examples include methylcarbamoyl, isopropylcarbamoyl and dimethylcarbamoyl est.
• Mono- or di-1-4C-alkylthiocarbamoyl residues are thiocarbamoyl residues (-CS-NH-) which are substituted by one or two identical or different of the above-mentioned 1-4C-alkyl residues.
• thiocarbamoyl residues thiocarbamoyl residues (-CS-NH-) which are substituted by one or two identical or different of the above-mentioned 1-4C-alkyl residues.
• the methylthiocarbamoyl, the isopropylthiocarbamoyl and the diethylthiocarbamoyl radical may be mentioned.
• the group C H. is preferably attached to a carbon atom of the cycle or bicyclus R6 in question, so that the radicals R6 (when R6 is a cycle or bicyclus) are, for example, the radicals: phenyl, 2-furyl, 3-furyl, 2 -Thienyl, 3-thienyl, 3-pyrrolyl, 2-0xazolyl, 4-0xazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 3-isothiazolyl, 2-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 1,2 , 3-triazol-4-yl, 1,2,5-thiazad-4-yl, l, 2,5-thiadiazol-4-yl-l-oxide, l, 2,4-triazol-3-yl , Tetrazol-5-yl, l, 3,4-thiadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,5-thiadia
• 1-4C-Alkoxycarbonyl stands for a radical which, in addition to the carbonyl group, contains one of the 1-4C-alkoxy radicals mentioned above.
• the methoxycarbonyl and the ethoxycarbonyl radical may be mentioned.
• radicals R6 which are substituted by R8 and R9 are: 4-methylphenyl, 3-dimethylaminomethylphenyl, 3-piperidinomethylphenyl, 3-carboxymethylphenyl, 2-dimethylaminomethyl-5-methyl-3-furyl, l-methylpyrrole-3 -yl, 4,5-dimethyl-oxazol-2-yl, 3,5-dimethyl-isoxazol-4-yl, 4,5-dimethyl-thiazol-2-yl, 4-methyl-5-carboxymethyl-thiazol-2 -yl, 1-methyl-imidazol -2-yl, 1-methyl-pyrazol-3-yl, l- ' (2-dimethylaminoethyl) -pyrazol-3-yl, 5-methyl-l, 3,4-oxadiazole- 2-yl, 1-methyl -1,2,3-
• residues -CH »- - r H 2r - and -C u H 2u - straight-chain or branched residues come into question.
• Examples include heptylene, isoheptylene (2-methylhexylene), hexylene, isohexylene (2-methylpentylene), neohexylene (2,2-dimethylbutylene), pentylene, isopentylene (3-methylbutylene) , Neopentylene (2,2-dimethylpropylene), butylene, iso-butylene, sec. Butylene, tert-butylene, propylene, isopropylene, ethylene and (for -CH «) the Methylene residue.
• radicals -CH "- are preferably the ethylene - (- CH 2 CH 2 -) and the butylene - (-CH 2 CH 2 CH 2 CH 2 -) and in particular the propylene radical (-CH 2 CH ⁇ H 2 -) call.
• the radicals —C. — preferably include the ethylene, propylene and butylene radicals.
• the radicals -CH «- are preferably the methylene, the ethylene and the propylene radical.
• u represents the number 0, so that the expression C U H 2 disappears or represents a hyphen and the radical R 6 is bonded directly to the group Y.
• Suitable salts for compounds of the formula I in which n denotes the number 0 are all acid addition salts.
• Pharmacologically incompatible salts which are initially used, for example, as process products in the preparation of the compounds according to the invention on an industrial scale. can fall, are converted into pharmacologically acceptable salts by processes known to the person skilled in the art.
• Suitable as such are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, Maleic acid, lauric acid, malic acid, fu aric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, the acids used in salt production - depending on whether it is a monobasic or polybasic acid and, depending on which salt is desired, can be used in an equi-olar or a different ratio.
• acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid,
• salts with bases are also suitable as salts.
• bases are lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidine salts, the bases also being here in the equimolar or in the salt production differing proportions are used.
• One embodiment of the invention is compounds of the formula I in which X has the meaning CH.
• a further embodiment of the invention are compounds of the formula I in which X has the meaning N.
• a further embodiment of the invention are compounds of the formula I in which t denotes the number 1.
• a further embodiment of the invention are compounds of the formula I in which u is a number from 1 to 7.
• a further embodiment of the invention are compounds of the formula I in which Y has the meaning 0 (oxygen).
• a further embodiment of the invention are compounds of the formula I in which X has the meaning CH, Y has the meaning S, t has the number 0 and u has the number 1 to 7.
• a further embodiment of the invention are compounds of the formula I in which X is CH, Y is S, t is 0, u is 0 and R4 is 1-4C-alkyl, 1-4C which is substituted by R14 -Alkylcarbonyl, 2-4C-alkenylcarbonyl, halogen-1-4C-alkylcarbonyl, N (R15) R16-1-4C-alkylcarbonyl, di-1-4C-alkylcarbamoyl or 1-4C-alkylsulfonyl.
• a further embodiment of the invention are compounds of the formula I in which Y is S, t is 0, u is 0 and R6 is a mono- or di-1-4C-alkylcarbamoyl or thiocarbamoyl radical, a N1 -4C-alkyl-N'-cyano-amidino radical, an INN-4C-alkylamino-2-nitroethyl radical, an N-2-propynyl-N'-cyano-amidino radical, an amino sulfonyl-amidino radical, or one by R8 and R9 are substituted cycles which are selected from the group consisting of thiadiazole-1-oxide, triazine, pyridone, imidazopyridine, benzothiazole and benzoxazole.
• a further embodiment of the invention are compounds of the formula I in which Y is NH or N-1-4C-alkyl, t is the number 0 and R5 is 1-4C-alkoxy.
• X represents CH or N
• YS, S0 denotes 2 , 0 or N-1-4C-alkyl
• R ' is hydrogen, l-4C-alkoxy or halogen
• R2 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy or halogen
• R3 means hydrogen
• R4 is hydrogen, 1-4C-alkyl substituted by R14,
• N is (R15) R16-1-4C-alkylcarbonyl or 1-4C-alkylsulfonyl
• R5 denotes hydrogen, 1-4C-alkyl or 1-4C-alkoxy
• R6 is a mono- or di-1-4C-alkylthiocarbamoyl radical, one
• NI-4C-alkyl-N'-cyano-amidino an INI-4C-alkylamino-2-nitroethylene, an N-2-propynyl-N'-cyano-amidino, or one through R8 and R9 are substituted cycles or bicycles, which is selected from the group consisting of benzene, furan, thiophene, oxazole, isoxazole, thiazole, thiazoline, isothiazole, imidazole, pyrazole, triazole, tetrazole, thiadiazole, thiadiazole-1-oxide, oxadiazole , Pyridine, pyrimidine, triazine, pyridone, benzidazole, imidazopyridine, benzothiazole and benzoxazole, R7 is hydrogen or 1-4C-alkyl, R8 is hydrogen, 1-4C-alkyl, hydroxy, nitro, guanidino, carboxy, 1-4
• R14 is hydroxy, 1-4C-alkoxycarbonyl or -N (R15) R16, where R15 is 1-4C-alkyl and R16 1-4C-alkyl, or wherein R15 and R16 together and including the nitrogen atom to which both are attached are a piperidino or morpholino radical, m is a number from 2 to 4, n is a number 0 or 1, p is a number 0, q is a number 0 or 2, r is a number from 2 to 4, t • the number 0 or 1 and u is a number from 0 to 3 and their salts, excluding those compounds of the formula I in which Y is Y and X is CH, t is 0 and u is 0 R4 denotes hydrogen and R6 denotes a cycle or bicyclus substituted by R8 and R9, which is selected from the group consisting of benzene, furan, thiophene, oxazole, isoxazole, thiazo
• X represents CH or N
• Rl is hydrogen, 1-4C-alkoxy or fluorine
• R2 is hydrogen, 1-4C-A1kyl or fluorine
• R3 means hydrogen
• R4 is hydrogen, 1-4C-A1kyl or 1-4C-A1kylsulfonyl substituted by R14,
• R5 denotes hydrogen or 1-4C-A1kyl
• R6 is a di-1-4C-alkylthiocarbamoyl residue, one
• Nl-4C-alkyl-N'-cyano-amidino radical or a cycle substituted by R8 and R9 which is selected from the group consisting of benzene, furan, thiophene, thiazole, imidazole, triazole, tetrazole, thiadiazole, pyridine, pyrimidine and Triazine,
• R7 represents hydrogen or 1-4C-A1kyl
• R8 denotes hydrogen, 1-4C-A1kyl, hydroxy, nitro, guanidino, carboxy, 1-4C-alkoxycarbonyl or 1-4C-A1kyl substituted by RIO,
• R9 denotes hydrogen, 1-4C-A1kyl, hydroxy or fluorine
• RIO is hydroxy, 1-4C-alkoxycarbonyl or -N (R11) R12, where
• R12 denotes 1-4C-A1kyl, or wherein
• R11 and R12 together and including the nitrogen atom to which both are attached represent a piperidino or morpholino radical
• R14 is 1-4C-alkoxycarbonyl or -N (R15) R16, where
• R16 is 1-4C-A1kyl, or wherein
• R15 and R16 together and including the nitrogen atom to which both are attached represent a piperidino or morpholino radical, are a number from 2 to 4, n is the number 0, p is the number 0, t is the number 0 and u is a number from 0 to 3 and their salts, excluding those compounds of the formula I in which Y is S and X is CH, u is 0, R4 is hydrogen and R6 is a substituted by R8 and R9 Cycle means which is selected from the group consisting of benzene, furan, thiophene, thiazole, imidazole, triazole, tetrazole, thiadiazole, pyridine and pyrimidine.
• Preferred compounds of formula I are those in which
• X represents CH or N
• Rl is hydrogen, 1-4C-alkoxy or fluorine
• R2 means hydrogen or fluorine
• R3 means hydrogen
• R4 means hydrogen
• R5 1 -4C-alkyl means
• R6 denotes a di-1-4C-alkylthiocarbamoyl residue or a cycle substituted by R8 and R9, which is selected from the group consisting of benzene, furan, thiophene, thiazole, imidazole, triazole,
• R7 is hydrogen
• R8 is hydrogen, nitro, 1-4C-alkoxycarbonyl or substituted by RIO
• 1-2C-alkyl means R9 is hydrogen or 1-4C-alkyl, RIO is 1-4C-alkoxycarbonyl or -N (R11) R12, where R11 is 1-4C-alkyl and R12 is 1-4C-alkyl, or wherein R11 and R12 together and including the nitrogen atom to which both are attached represent a piperidino or morpholino radical, m denotes the number 2 or 3, n denotes the number 0, p denotes the number 0, t denotes the number 0 and u is a number from 1 to 3 and their salts.
• An embodiment of the preferred compounds are those in which X has the meaning CH.
• a further embodiment of the preferred compounds are those in which X has the meaning N.
• a further embodiment of the preferred compounds are those in which Y has the meaning S.
• Another embodiment of the preferred compounds are those in which R1 and R2 are hydrogen.
• a further embodiment of the preferred compounds are those in which u denotes the number 1.
• a further embodiment of the preferred compounds are those in which u is the number 2.
• a further embodiment of the preferred compounds are those in which m denotes the number 2.
• Another embodiment of the preferred compounds are those in which m is 3.
• X represents CH or N
• Rl is hydrogen
• R2 means hydrogen
• R3 means hydrogen
• R4 means hydrogen
• R5 denotes 1-4C-alkyl
• R6 denotes a cycle substituted by R8 and R9, which is selected from the group consisting of benzene, furan, thiophene, thiazole, imidazole, triazole, tetrazole, thiadiazole, pyridine and pyrimidine,
• R7 means hydrogen
• R8 nitro means
• R9 is hydrogen or 1-4C-alkyl, the number 2 or 3, n the number 0, p the number 0, t the number 0 and u a number from 1 to 3 and their salts.
• X represents CH or N
• Rl is hydrogen
• R2 means hydrogen
• R3 means hydrogen
• R4 means hydrogen
• R5 denotes 1-4C-alkyl
• R6 denotes imidazole substituted by R8 and R9
• R7 means hydrogen
• R9 denotes hydrogen or 1-4C-alkyl
• m denotes the number 2 or 3
• n denotes the number 1
• p denotes the number 1
• t denotes the number 0
• u denotes a number from 1 to 3 and their salts.
• NSHHH CH 3 4-pyridinyl H 3 • - 0 0
• NSHHH CH 3 4-methyl-l, 2,4-triazol-3- • yi H 3 - - 0 1
• Another object of the invention is a process for the preparation of the compounds of formula I and their salts.
• the process is characterized in that
• benzimidazoles of the formula VII (see enclosed formula sheet II), in which R1, R2, R3, R4 and X have the meanings indicated above and A represents a suitable leaving group, with pyridines of the formula VIII (see enclosed formula sheet II), in which R5, R6, R7, Y, m, p, q, r, t and u have the meanings given above, and
• Suitable leaving groups A include, for example, halogen atoms, in particular chlorine, or hydroxyl groups activated by esterification (for example with p-toluenesulfonic acid).
• the reaction of II with III takes place in suitable, preferably polar, protic or aprotic solvents (such as methanol, ethanol, isopropanol, diethyl sulfoxide, acetone, dimethylfor amide or acetonitrile) with the addition or exclusion of water. It is carried out, for example, in the presence of a proton acceptor.
• suitable, preferably polar, protic or aprotic solvents such as methanol, ethanol, isopropanol, diethyl sulfoxide, acetone, dimethylfor amide or acetonitrile
• a proton acceptor Alkali metal hydroxides, such as sodium hydroxide, alkali metal carbonates, such as potassium carbonate, or tertiary amines, such as pyridine, triethylamine or ethyldiisopropylamine, are suitable as such.
• reaction can also be carried out without a proton acceptor, with the acid addition salts optionally being able to be separated off in a particularly pure form, depending on the nature of the starting compounds.
• the reaction temperature can be between 0 ⁇ and 150 ⁇ C, in the presence of proton acceptors temperatures between 20 ° and 80 ⁇ C and without proton acceptors between 60 ° and 120 ° C - in particular the boiling point of the solvents used - are preferred.
• the reaction times are between 0.5 and 30 hours.
• the reaction of the compounds V with the thiols VI takes place in a manner known per se, as is known to the person skilled in the art for the production of sulfides from thiols and halogenated aroids.
• the halogen atom shark is preferably a chlorine atom.
• Suitable oxidizing agents are all reagents customarily used for the oxidation of sulfides to sulfoxides or sulfones, in particular peroxy acids, such as peroxyacetic acid, trifluoroperoxyacetic acid, 3,5-dinitroperoxybenzoic acid, peroxy-aleic acid, magnesium monoperoxiphthalate or preferably m-chloroperoxybenzoic acid.
• peroxy acids such as peroxyacetic acid, trifluoroperoxyacetic acid, 3,5-dinitroperoxybenzoic acid, peroxy-aleic acid, magnesium monoperoxiphthalate or preferably m-chloroperoxybenzoic acid.
• the reaction temperature is (depending on the reactivity of the oxidizing agent and degree of dilution) between -70T and the boiling point of the solvent used, but preferably between -30 ° and + 20 ° C.
• An advantageous also the oxidation with halogens or with hypohalites has been found (for example with aqueous sodium hypochlorite solution), which is expediently carried out at temperatures between 0 ° C and 50 ⁇ .
• reaction is advantageously carried out in inert solvents, for example aromatic or chlorinated hydrocarbons, such as benzene, toluene, dichloromethane or chloroform, preferably in esters or ethers, such as ethyl acetate, isopropyl acetate or dioxane, or in alcohols, preferably isopropanol , carried out.
• aromatic or chlorinated hydrocarbons such as benzene, toluene, dichloromethane or chloroform
• esters or ethers such as ethyl acetate, isopropyl acetate or dioxane
• alcohols preferably isopropanol
• the sulfoxides according to the invention are optically active compounds. Depending on the nature of the substituents, there may be additional chiral centers in the molecule.
• the invention therefore includes both the enantiomers and diastereomers and their mixtures and racemates.
• the enantiomers can be separated in a manner known per se (for example by preparing and separating corresponding diastereoiso compounds) (see, for example, WO92 / 08716).
• Compounds II are e.g. known from W086 / 02646, EP 134400 or EP 127 763.
• the respective sulfides or sulfoxides or sulfones can be prepared by choosing suitable starting compounds or by using selective oxidizing agents.
• the starting compounds required for the preparation of III can e.g. can be prepared from the corresponding halogen compounds analogously to J. Med. Chem. 14 (1971) 349.
• the compounds V, VI, VII and VIII are also known or they can be prepared in an analogous manner from known starting compounds by processes known per se.
• compounds of the formula V are obtained by reacting compounds of the formula II with 4-halopyridines corresponding to compounds of the formula III.
• Example 2 The procedure described in Example 1 is followed by reaction of 2 - ⁇ [[4- (2-chloroethylthio) -3-methyl-2-pyridinyl] methyl] thio) -lH-benzimidazole with 4-methyl-benzyl mercaptan Recrystallization from methanol / toluene the title compound; M.p. 129-130 ⁇ C; Education: 55% of theory 4. 2-f rr4-r3-Dimethyldithiocarbamo y l-pro p ylthiol-3-methyl-2-pyridinvnme- thylI hiollH-benzimidazole
• the free title compound is obtained as an oil by reaction with 5-dimethylaminomethyl-2-furylmethylthiol.
• the title compound can be precipitated as hydrochloride from acetone using gaseous hydrochloric acid; M.p. 112 ⁇ C (dec.).
• the free base of the title compound is obtained as an oil by reaction with 1 - [(2-dimethylamino) ethyl] -5-mercaptotetrazole. It is used with conc. Hydrochloric acid in acetone a hydrochloride and receives the title compound as a colorless solid; M.p. 81-83'C; Education: 39% of theory
• Example A2.a According to the procedure given in Example A2.a), the title compound is obtained as an oily residue by reacting 4-chloro-2,3-dimethylpyridine-N-oxide with 2-mercaptoethanol and sodium hydride and is used in the subsequent step without further purification becomes.
• Example A2.b According to the procedure given in Example A2.b), by reacting the oil obtained under a) with acetic anhydride and then saponifying with NaOH, the title compound is obtained as an oily residue which is used in the subsequent step without further purification.
• Example A2.c the title compound is obtained as an oily residue by reacting the oil obtained under b) with thionyl chloride, which is used directly as a solution in ethanol for reaction with 2-mercaptobenzi idazole.
• the invention therefore furthermore relates to a method for the treatment of mammals, in particular humans, who are suffering from diseases which are based on Helicobacter bacteria.
• the method is characterized in that the diseased individual is administered a therapeutically effective and pharmacologically tolerable amount of one or more compounds of the formula I and / or their pharmacologically tolerable salts.
• the invention also relates to the compounds of the formula I and their pharmacologically tolerable salts for use in the treatment of diseases which are based on Helicobacter bacteria.
• the invention also encompasses the use of compounds of the formula I and their pharmacologically tolerable salts in the preparation of medicaments which are used to combat diseases which are based on Helicobacter bacteria.
• the invention further relates to medicaments for combating Helicobacter bacteria which contain one or more compounds of the general formula I and / or their pharmacologically tolerable salts.
• the Helicobacter pyori strain in particular should be mentioned.
• the pharmaceuticals are produced by methods known per se and familiar to the person skilled in the art.
• the pharmacologically active compounds of the formula I and their salts (“active ingredients) are used as pharmaceuticals either as such or preferably in combination with suitable pharmaceutical auxiliaries, for example in the form of tablets, dragées, capsules, emulsions, suspensions. pensions, gels or solutions are used, the active substance content advantageously being between 0.1 and 95%.
• auxiliaries suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
• active substance carriers for example antioxidants, dispersants, emulsifiers, defoamers, taste correctives, preservatives, solubilizers, colorants or permeation promoters and complexing agents (e.g. cyclodextrins) can be used.
• the active ingredients can, for example, parenterally (z '.B. Intravenously) or ins ⁇ particular orally be administered.
• the active ingredients in human medicine are administered in a daily dose of about 0.2 to 50, preferably 1 to 30 mg / kg of body weight, optionally in the form of several, preferably 2 to 6, individual doses to achieve the desired result .
• the compounds of the formula I in which n is the number 0, are effective against Helicobacter bacteria when the doses are administered, which are below the doses used for education gastric acid secretion inhibition - sufficient for therapeutic purposes.
• n denotes the number 1
• these compounds can also be used to treat such diseases are based on an elevated f agenklaresekretion.
• the compounds according to the invention can also be administered in a fixed or free combination together with a substance which neutralizes gastric acid and / or inhibits gastric acid secretion and / or with a substance suitable for the classic control of Helicobacter pylori.
• substances which neutralize gastric acid are sodium bicarbonate or other antacids (such as aluminum hydroxide, magnesium aluminumate or magaldrate).
• H 2 blockers for example cimetidine, ranitidine
• H + / K + -ATPase inhibitors for example lansoprazole, omeprazole or in particular pan-toprazole
• peripheral anticholinergics for example pirenzepin, telenzenpin
• Substances suitable for the classic control of Helicobacter pylori are, in particular, antimicrobially active substances, such as, for example, penicillin G, gentamycin, erythrocin, nitrofurazone, tinidazole, nitrofurantoin, furazolidone, metronidazole and in particular amoxyciline, or else bismuth salts such as called bismuth triumvirate.
• antimicrobially active substances such as, for example, penicillin G, gentamycin, erythrocin, nitrofurazone, tinidazole, nitrofurantoin, furazolidone, metronidazole and in particular amoxyciline, or else bismuth salts such as called bismuth triumvirate.
• the compounds of the formula I were tested for their activity against Helicobacter pylori based on that of Tomoyuki Iwahi et al. (Antimicrobial Agents and Chemotherapy, 1991, 490-496) methodology described using Colobia agar (Oxoid) and examined with a growth period of 4 days.
• the approx. MIC 50 values listed in Table A below resulted for the compounds examined (the numbers of the compounds given correspond to the example numbers in the description).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Other Air-Conditioning Systems (AREA)
• Mounting Of Printed Circuit Boards And The Like (AREA)
• Air Filters, Heat-Exchange Apparatuses, And Housings Of Air-Conditioning Units (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=4219963

Family Applications (1)

Country Status (19)

Families Citing this family (17)

Family Cites Families (12)

• 1995
  • 1995-06-09 CZ CZ19963624A patent/CZ288079B6/cs not_active IP Right Cessation
  • 1995-06-09 PL PL95317613A patent/PL181801B1/pl unknown
  • 1995-06-09 HU HU9603339A patent/HU220062B/hu not_active IP Right Cessation
  • 1995-06-09 JP JP8501598A patent/JPH10501254A/ja not_active Withdrawn
  • 1995-06-09 CA CA002192202A patent/CA2192202A1/en not_active Abandoned
  • 1995-06-09 FI FI964909A patent/FI964909L/fi unknown
  • 1995-06-09 AU AU27901/95A patent/AU697572B2/en not_active Ceased
  • 1995-06-09 US US08/750,785 patent/US5859030A/en not_active Expired - Fee Related
  • 1995-06-09 EE EE9600189A patent/EE03312B1/xx not_active IP Right Cessation
  • 1995-06-09 RO RO96-02255A patent/RO117792B1/ro unknown
  • 1995-06-09 EP EP95923288A patent/EP0764161A1/de not_active Withdrawn
  • 1995-06-09 CN CN95194562A patent/CN1070488C/zh not_active Expired - Fee Related
  • 1995-06-09 SK SK1576-96A patent/SK281465B6/sk unknown
  • 1995-06-09 WO PCT/EP1995/002237 patent/WO1995034554A1/de not_active Ceased
  • 1995-06-09 RU RU97100641/04A patent/RU2139286C1/ru not_active IP Right Cessation
  • 1995-06-09 NZ NZ288609A patent/NZ288609A/xx unknown
• 1996
  • 1996-11-21 BG BG101002A patent/BG63502B1/bg unknown
  • 1996-12-03 NO NO19965162A patent/NO311618B1/no unknown
  • 1996-12-10 MX MX9606300A patent/MX9606300A/es not_active IP Right Cessation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events